Kalkine has a fully transformed New Avatar.
Last update at 2025-07-02T06:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is Imricor Medical Systems (ASX:IMR) In A Good Position To Invest In Growth?
Wed 04 May 22, 08:52 PMHow Much Of Imricor Medical Systems, Inc. (ASX:IMR) Do Insiders Own?
Tue 01 Feb 22, 11:31 PMWill Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?
Mon 01 Nov 21, 02:38 AMDo Insiders Own Lots Of Shares In Imricor Medical Systems, Inc. (ASX:IMR)?
Fri 02 Jul 21, 05:13 PMHere's Why We're Not Too Worried About Imricor Medical Systems' (ASX:IMR) Cash Burn Situation
Mon 03 May 21, 05:09 PMImricor Medical Systems, Inc.'s (ASX:IMR) Shift From Loss To Profit
Thu 04 Mar 21, 04:33 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -17.35627M | -19.73254M | -12.44647M | -13.29398M | -5.44848M |
Minority interest | - | - | - | - | - |
Net income | -17.53418M | -20.55611M | -13.07680M | -14.79815M | -5.44848M |
Selling general administrative | 4.98M | 5.82M | 4.33M | 2.64M | 2.29M |
Selling and marketing expenses | 2.80M | 2.87M | 1.68M | 0.57M | - |
Gross profit | -1.52678M | -1.89592M | -0.39767M | 0.26M | 1.00M |
Reconciled depreciation | 0.71M | 0.69M | 0.53M | 0.26M | - |
Ebit | -17.17835M | -19.62369M | -12.14584M | -12.26324M | -4.81724M |
Ebitda | -16.46586M | -18.93458M | -11.61775M | -12.00594M | - |
Depreciation and amortization | 0.71M | 0.69M | 0.53M | 0.26M | - |
Non operating income net other | - | - | - | - | - |
Operating income | -17.17835M | -19.62369M | -11.61775M | -12.00594M | -4.81724M |
Other operating expenses | 18.81M | 21.74M | 13.21M | 13.39M | - |
Interest expense | 0.18M | 0.11M | 0.30M | 1.03M | 0.00000M |
Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Interest income | 0.11M | 0.02M | 0.04M | 0.80M | 0.63M |
Net interest income | -0.06992M | -0.09212M | -0.35238M | -1.45144M | - |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 0.18M | 0.82M | 0.63M | 1.50M | - |
Total revenue | 0.82M | 0.70M | 0.70M | 0.64M | 1.00M |
Total operating expenses | 16.47M | 19.15M | 12.11M | 13.01M | 5.82M |
Cost of revenue | 2.34M | 2.59M | 1.10M | 0.38M | - |
Total other income expense net | -0.17792M | -0.10885M | -0.82873M | -1.28803M | -0.63124M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -17.35627M | -19.73254M | -16.16005M | -18.97513M | -5.44848M |
Net income applicable to common shares | -17.35627M | -19.73254M | -12.44647M | -13.29398M | -5.44848M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
Total assets | 21.62M | 12.18M | 13.70M | 26.86M | 33.57M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 0.79M | 1.52M | 1.59M | 1.51M | 0.49M |
Total liab | 29.00M | 25.00M | 6.19M | 4.46M | 4.75M |
Total stockholder equity | -7.37703M | -12.82827M | 7.51M | 22.40M | 28.82M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 1.55M | 1.16M | 0.02M | 0.18M | 0.50M |
Common stock | 0.03M | 0.02M | 97.47M | 95.01M | 81.69M |
Capital stock | - | - | 97.47M | 95.01M | 81.69M |
Retained earnings | -142.27972M | -164.99880M | -89.96098M | -72.60472M | -52.87218M |
Other liab | - | - | 0.54M | 0.51M | 0.62M |
Good will | - | - | - | - | - |
Other assets | - | - | 0.23M | 0.57M | 0.75M |
Cash | 15.71M | 1.22M | 5.69M | 18.52M | 25.14M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 2.36M | 6.70M | 2.07M | 2.74M | 2.30M |
Current deferred revenue | - | 0.85M | 0.92M | 1.35M | 1.07M |
Net debt | 5.51M | 14.48M | -1.19781M | -16.77856M | -23.75387M |
Short term debt | 0.47M | 1.60M | 0.87M | 0.52M | 0.20M |
Short long term debt | - | - | - | - | - |
Short long term debt total | 21.21M | 15.70M | 4.49M | 1.74M | 1.39M |
Other stockholder equity | 134.88M | 152.15M | - | - | 2.14M |
Property plant equipment | - | - | 3.56M | 3.60M | 3.89M |
Total current assets | 18.35M | 5.77M | 9.68M | 22.70M | 28.92M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | - | 7.51M | 22.40M | 28.82M |
Short term investments | - | - | - | - | - |
Net receivables | 0.35M | 0.58M | 0.13M | 0.09M | 0.22M |
Long term debt | - | - | 2.18M | - | - |
Inventory | 1.50M | 2.46M | 2.28M | 2.58M | 3.07M |
Accounts payable | 0.33M | 3.08M | 0.26M | 0.69M | 0.53M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - | -2.13881M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | 106.06M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.68M | 1.49M | 0.46M | 0.57M | 0.75M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 3.27M | 6.40M | 4.02M | 4.17M | 4.64M |
Capital lease obligations | - | - | 2.31M | 1.74M | 1.80M |
Long term debt total | - | - | 2.25M | 0.23M | 0.67M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -0.23886M | -0.06956M | -1.00498M | -0.75555M | -0.06956M |
Change to liabilities | -0.57287M | 0.24M | -0.29858M | 0.26M | -0.25280M |
Total cashflows from investing activities | -0.23886M | -0.69530M | -0.77403M | -0.52934M | -0.15059M |
Net borrowings | 1.97M | -0.58130M | -0.38244M | 3.23M | 4.74M |
Total cash from financing activities | 3.94M | 11.59M | 33.02M | 10.45M | 4.70M |
Change to operating activities | 0.11M | -0.60549M | 0.74M | 0.18M | 0.01M |
Net income | -17.53418M | -19.73254M | -12.97456M | -13.55128M | -5.44848M |
Change in cash | -12.82839M | -6.62360M | 20.09M | 3.46M | -0.18073M |
Begin period cash flow | 18.52M | 25.14M | 5.05M | 1.59M | - |
End period cash flow | 5.69M | 18.52M | 25.14M | 5.05M | 2.27M |
Total cash from operating activities | -16.82169M | -17.48855M | -12.23069M | -6.62799M | -4.73385M |
Issuance of capital stock | 4.37M | 12.17M | 33.41M | 7.22M | - |
Depreciation | 0.71M | 0.69M | 0.53M | 0.26M | 0.08M |
Other cashflows from investing activities | 0.00000M | -0.06956M | -0.03215M | -0.16458M | -0.00386M |
Dividends paid | - | - | - | - | - |
Change to inventory | -0.44497M | -0.18136M | -1.84930M | -0.84630M | -0.22640M |
Change to account receivables | -0.06822M | 0.15M | 0.07M | -0.16097M | 0.03M |
Sale purchase of stock | -0.07067M | 12.17M | 33.41M | 7.22M | 0.01M |
Other cashflows from financing activities | 0.51M | -0.58130M | -0.38244M | 3.23M | -0.04935M |
Change to netincome | 1.01M | 1.94M | 1.02M | 2.67M | 0.82M |
Capital expenditures | 0.24M | 0.63M | 0.74M | 0.36M | 0.15M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -0.97767M | -0.38914M | -1.33266M | -0.56636M | -0.44087M |
Stock based compensation | - | - | - | - | - |
Other non cash items | 16.82M | 19.04M | 11.92M | 13.29M | - |
Free cash flow | -17.06055M | -18.11429M | -12.97258M | -6.99275M | - |
Sector: Healthcare Industry: Medical Devices
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
IMR Imricor Medical Systems Inc |
0.01 0.97% | 1.56 | - | - | 516.70 | 3.97 | 347.39 | -2.6027 |
COH Cochlear Ltd |
-2.91 0.96% | 301.65 | 52.49 | 44.25 | 8.40 | 10.41 | 8.36 | 32.31 |
PNV Polynovo Ltd |
-0.02 1.67% | 1.18 | 120.70 | 55.56 | 7.21 | 10.66 | 6.85 | 86.08 |
EBR Ebr Systems Inc CDR |
-0.015 1.29% | 1.15 | - | - | - | 19.96 | -3.6785 | |
AVR Anteris Technologies Ltd |
-0.29 4.84% | 5.70 | - | - | 91.86 | 3.31 | 38.26 | -5.1986 |
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company's product includes the Advantage-MR EP Recorder/Stimulator system, an EP recording system and cardiac stimulator. Its products also include Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
400 Gateway Boulevard, Burnsville, MN, United States, 55337
Name | Title | Year Born |
---|---|---|
Mr. Steve Wedan | Pres, CEO & Exec. Chairman | 1969 |
Mr. Gregg Stenzel | Chief Operating Officer | NA |
Mr. Jonathon Gut | CFO, Controller, Director & VP of Fin. | NA |
Mr. Greg Englehardt | Exec. Director of Sales | NA |
Mr. Nick Twohy | VP of Marketing & Bus. Devel. | NA |
Mr. Kobe Lizheng | Company Sec. & Local Agent | NA |
Mr. Steve Wedan | President, CEO & Executive Chairman | 1969 |
Mr. Jonathon Gut | CFO, Controller, Director & VP of Finance | NA |
Mr. Greg Englehardt | Senior Director of Sales | NA |
Mr. Steve Wedan | President, CEO & Executive Chairman | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.